Trump's unilateral tariff actions on Indian pharmaceutical exports (100% from 2028, rising to 200%) and use of Sections 301, 232, and 338 expose the fragility of ongoing India-US trade negotiations. Despite $150 billion bilateral trade and India's surplus, no signed agreement seems safe. India should prioritize trade diversification towards the UK and EU.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Bilateral Trade (2025): $150 billion
- ›Pharma Tariff Announcement: 100% from 2028, 200% from 2029
- ›Target this Data: Bilateral trade $150 billion (2025); Pharma tariff 100% from 2028, 200% from 2029
- ›Target this Nodal Body: Office of the United States Trade Representative (USTR) - Jamieson Greer mentioned
- ›Target this Legal Point: Sections 301, 232, and 338 of the US Tariff Act of 1930
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.